Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / December 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. ("Anavex" or "the Company") (NASDAQ:AVXL). Investors who purchased Anavex securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AVXL.

Investigation Details

On November 14, 2025, Anavex issued a press release announcing that "[t]he Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its CHMP oral explanation." Following this news, Anavex's stock price dropped $2.05 per share, or 35.94%, to close at $3.65 on November 14, 2025.

What's Next?

If you are aware of any facts relating to this investigation or purchased Anavex securities, you can assist this investigation by visiting the firm's site: bgandg.com/AVXL. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC